Nipah Open Library

Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials

Revision as of 01:56, 7 February 2026 by Nhmkerala (talk | contribs) (Created paper page - 2026-02-07T07:26:28.660963)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Authors: Xin Hui S Chan, Ilsa L Haeusler, Bennett J K Choy, Md Zakiul Hassan, Junko Takata, Tara P Hurst, Luke M Jones, Shanghavie Loganathan, Elinor Harriss, Jake Dunning, Joel Tarning, Miles W Carroll, Peter W Horby, Piero L Olliaro

Year: 2024

Journal: Review

DOI: 10.xxxx/xxxxx

Summary

This paper reviews the safety and efficacy of therapeutic options for Nipah virus disease to prioritize drug candidates for further evaluation in clinical trials, suggesting trialling 1F5, m102.4, and remdesivir (alone or in combination) for prophylaxis and early treatment.

Key Findings

  • Trialling 1F5, m102.4, and remdesivir for prophylaxis and early treatment of Nipah virus disease
  • Well designed clinical efficacy trials and in-vivo pharmacokinetic–pharmacodynamic studies needed to optimise therapeutic candidates

Methodology

  • Study Type: Review
  • Sample Size: Not specified
  • Geographic Focus: Malaysia, Singapore, Bangladesh, India
  • Time Period: 1998-present

Topics

Therapeutics, Nipah virus disease

Relevance

The paper discusses the urgent need for approved therapeutics or vaccines to treat Nipah virus disease due to its high case-fatality rate and potential for a pandemic.

Source

View the entire paper: File:PIIS2666524724002702.pdf

Retrieved from "https://nipahlib.phenomi.co/index.php?title=Therapeutics_for_Nipah_virus_disease:_a_systematic_review_to_support_prioritisation_of_drug_candidates_for_clinical_trials&oldid=188"